Semax: Research Overview

The short version

Semax is a lab-made peptide built from a fragment of the natural hormone ACTH, with a three-amino-acid tail added to slow its breakdown. In rodent studies, it produces fast, brain-region-specific changes in BDNF and NGF, proteins involved in the growth, connection and survival of nerve cells ^[3][4].

Most of the evidence comes from animal studies of stroke, spinal-cord injury and neurotrophin signaling. The published record also includes older clinical work from Russian medical practice, but no comparable body of independently replicated Western trials. Semax is not FDA-approved for human use; its prescription registration is limited to Russia and Ukraine for specific indications. Community reports about focus and mental clarity appear later on this page and are labeled as anecdotal rather than clinical findings. This page explains the research record only. It does not recommend using semax, and any study amount mentioned describes that experiment rather than a dose for a person.

What it is

Semax (systematic name Met-Glu-His-Phe-Pro-Gly-Pro, sometimes written MEHFPGP) is a synthetic linear heptapeptide. It combines the native ACTH(4-7) fragment — Met-Glu-His-Phe, a piece of the larger adrenocorticotropic hormone molecule — with a Pro-Gly-Pro (PGP) tripeptide grafted onto the end. That added tail is the key design feature: it slows the enzymes that would otherwise break the peptide down within minutes, extending how long it survives in circulation and in brain tissue. Because the steroidogenic (cortisol-releasing) portion of full-length ACTH is not present, semax does not carry ACTH's hormonal effect on the adrenal glands.

It is most commonly supplied and studied as an intranasal solution, and often as the acetate salt. Pharmacokinetic tracer work found that after a single intranasal dose in rats, only a small fraction of the administered dose reached brain tissue within two minutes, and even then, roughly a fifth of that material had already been broken down into metabolites — a signature of a peptide that acts fast and clears fast ^[6].

How it works

Semax's best-characterized mechanism is neurotrophin signaling. A single intranasal dose in rats produced rapid, region-specific changes in NGF and BDNF messenger RNA — rising in the hippocampus, rising in brainstem and cerebellum for BDNF specifically, and actually falling in frontal cortex for NGF — inside hours of dosing ^[3]. A separate study found the same rapid, region-specific pattern at the protein level: BDNF protein rose in basal forebrain (but not cerebellum) three hours after dosing, and the peptide bound a specific, reversible, calcium-dependent binding site with a dissociation constant around 2.4 nanomolar ^[4].

A second, distinct mechanism runs through the endogenous opioid system: in human serum tested outside the body, semax inhibited enkephalin-degrading enzymes with a potency greater than several reference inhibitors, which is thought to prolong the activity of the body's own opioid-family signaling peptides ^[7]. In models of brain injury, semax's protective effect appears to be driven less by any single receptor and more by a broad shift in gene expression toward immune modulation and improved blood-vessel function — a genome-wide analysis after induced stroke in rats found immune-system genes made up more than half of all genes affected, with a distinct wave of vascular-gene changes as well ^[2].

What the research shows

Spinal-cord injury (2025). In female mice with a surgically induced spinal-cord injury, semax improved functional recovery — measured by locomotor scoring, an inclined-plane test, and footprint analysis — and reduced a specific form of cell death (pyroptosis) by acting on the mu-opioid-receptor gene Oprm1 through a defined molecular pathway involving the proteins USP18 and FTO ^[1].

Ischemic stroke — gene expression (2014). A genome-wide transcriptional analysis after permanent middle-cerebral-artery occlusion in rats found semax predominantly modulated immune-system genes — immunoglobulins and chemokines made up more than half of all affected genes — alongside a separate set of vascular-system genes altered at 3 and 24 hours, framing immunomodulation and vascular regulation as key to its neuroprotective effect ^[2].

Neurotrophin gene and protein expression (2006–2007). Two rat studies established the core mechanism: rapid, region-specific changes in NGF and BDNF mRNA after a single 50-microgram-per-kilogram intranasal dose ^[3], and a matching rise in BDNF protein in basal forebrain at three hours, alongside characterization of a specific, reversible, calcium-dependent binding site (KD ≈ 2.4 nM) ^[4].

Ischemia and memory (2006). In a rat model of focal photoinduced prefrontal-cortex ischemia, six days of intranasal semax decreased the volume of cortical infarction and improved retention of a learned avoidance response — an antiamnesic effect on top of the neuroprotective one ^[5].

Pharmacokinetics (2006). Radiolabeled tracer work showed semax reaches brain tissue within about two minutes of intranasal dosing in rats, with roughly four-fifths of the brain-associated radioactivity still representing intact peptide at that point and the remainder already metabolized — evidence of fast onset paired with fast clearance ^[6].

Enkephalinase inhibition (2001). In human serum tested in vitro, semax inhibited enkephalin-degrading enzymes with an IC50 around 10 micromolar — more potent than several reference inhibitors and than selank in the same assay — supporting the proposed endogenous-opioid mechanism ^[7].

Reported effects, cautions & safety

The following community-reported effects are anecdotal, not clinical evidence. They come from nootropics forums, biohacker writeups and peptide-user discussion, not controlled trials.

People most often describe clear-headed focus, quiet task persistence and, less often, easier word recall. A meaningful minority reports a subtle effect or none at all; some describe feeling flat. Other reports include fatigue as the effect fades, headache, irritability when combined with stimulants, and burning or congestion with intranasal preparations. These accounts are useful for mapping expectations, but they cannot establish efficacy or frequency.

The literature supports a separate set of cautions:

• Sourcing and purity are unregulated. Consumer research-chemical material has no required testing of identity, purity or sterility, and it is not the material used in the published pharmacology.
• Long-term human safety remains unclear. Most mechanistic and efficacy work is in rodents, while clinical experience is concentrated in Russia and Ukraine ^[3][2][4].
• The intranasal route can irritate nasal tissue, and research-grade solutions lack pharmacy controls for sterility and pH ^[6].
• Drug interactions are unstudied. Semax's effects on endogenous-opioid signaling create an uncertain interaction surface with opioid-active and other neuroactive drugs ^[7].
• Neurotrophin and gene-expression changes are not trivial, and the consequences of repeated exposure in a healthy human brain have not been mapped ^[3][4][2].
• Pregnancy, breastfeeding and major pre-existing conditions are uncharacterized. No validated human dosing, cycling or tolerance framework follows from this literature.

Where it fits in Cognitive & Nootropic research

Within this desk's neuroplasticity frame, semax is the compound with the clearest and most direct neurotrophin story: a fast, region-specific rise in BDNF and NGF that is mechanistically distinct from selank's GABAergic route to a similar hippocampal BDNF endpoint, and structurally unrelated to DSIP's sleep-and-stress-axis focus. Semax's evidence base is also the largest of the three on this site, spanning stroke, spinal-cord injury and gene-expression work — though, like the other two, it remains overwhelmingly a Russian and rodent literature without independent Western clinical trials. See the comparison page for how all three line up.